stockrow
Friday 6 November 2026
Export CV’s income statement to Excel — free account
CapsoVision, Inc.
CapsoVision, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $13.6 million, up 15.3% from fiscal 2024.
- Revenue
- +9.89%
- EPS
- +92.6%
- Free cash flow
- −84.4%
Quarter to June 2026, against a year earlier
6.18
0.02
−0.32%
Follow CV
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | 12 | 14 | 14 | +15.3% | 15 | 20 | 41 | +44.6% | |
| Gross margin, % | — | — | — | — | — | — | — | — | 54.24 | 52.92 | 50.88 | (1.3) pt | ||||||
| EBT | — | — | — | — | — | — | — | — | (20) | (25) | (30) | +27.2% | ||||||
| EBT margin, % | — | — | — | — | — | — | — | — | (169.16) | (186.59) | (214.56) | (17.4) pt | ||||||
| Net income | — | — | — | — | — | — | — | — | (20) | (25) | (30) | +27.2% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | — | 5.82 | 0.55 | 0.28 | (90.5%) | |||||
| Earnings | — | — | — | — | — | — | — | — | (9.85) | (1.03) | (0.63) | (89.5%) | ||||||
| Cash flow | — | — | — | — | — | — | — | — | (9.95) | (0.93) | (0.56) | (90.6%) | ||||||
| Capex | — | — | — | — | — | — | — | — | (0.08) | 0.00 | 0.00 | (95.1%) | ||||||
| Free cash flow | — | — | — | — | — | — | — | — | (10.02) | (0.93) | (0.56) | (90.7%) | ||||||
| Book value | — | — | — | — | — | — | — | — | (64.11) | 0.54 | 0.26 | n/m | ||||||
| Shares, m | — | — | — | — | — | — | — | — | 2 | 25 | 42 | +1,115.6% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | — | — | — | — | — | — | — | 0.67 | 19.37 | 22.18 | 10.0 | ||||||
| P/B | — | — | — | — | — | — | — | — | 0.00 | 19.80 | 23.40 | 9.9 | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | 0.58 | 18.62 | 21.53 | 9.6 | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | (0.32) | (11.00) | (10.72) | (5.7) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | — | (20) | (23) | (28) | +13.8% | |||||
| Capex | — | — | — | — | — | — | — | — | 0 | 0 | 0 | (41.2%) | ||||||
| Free cash flow | — | — | — | — | — | — | — | — | (20) | (23) | (28) | +13.4% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | — | 13 | 12 | 12 | (6.2%) | |||||
| Net debt | — | — | — | — | — | — | — | — | (9) | (10) | (9) | +8.5% | ||||||
| Shareholders’ equity | — | — | — | — | — | — | — | — | (130) | 13 | 13 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | — | 0.00 | (144.79) | (212.19) | (144.8) pt | |||||
| ROIC | — | — | — | — | — | — | — | — | 0.00 | (506.59) | (460.93) | (506.6) pt | ||||||
| ROE | — | — | — | — | — | — | — | — | 0.00 | 43.55 | 47.42 | +43.6 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | 90 | 28 | — | (68.9%) | |||||
| Revenue/emp, $m | — | — | — | — | — | — | — | — | 0.13 | 0.48 | — | +270.6% | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 26 Oct 2026
CapsoVision, Inc. vs peers in Medical Devices (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| BWAY Brainsway Ltd. Sponsored ADR | $427.1M | 21.2× | — (loss-making) | +35.43% (above 0%: growing) | +40.00% (above 0%: growing) | −51.68% (below 0%: shrinking) | 74.62% | 13.98% | Compare |
| SI Shoulder Innovations, Inc. | $424.1M | — (loss-making) | — (loss-making) | +37.73% (above 0%: growing) | n/m | +38.63% (above 0%: growing) | 78.47% | (46.92%) | Compare |
| RCEL Avita Medical Inc. | $389.5M | — (loss-making) | — (loss-making) | +53.05% (above 0%: growing) | n/m | +86.66% (above 0%: growing) | 84.02% | (17.95%) | Compare |
| MOBI Mobia Medical, Inc | $375.5M | — (loss-making) | — (loss-making) | +175.85% (above 0%: growing) | n/m | −18.01% (below 0%: shrinking) | 83.25% | (118.67%) | Compare |
| OFIX ORTHOFIX MEDICAL INC. | $363.3M | — (loss-making) | — (loss-making) | +3.85% (above 0%: growing) | n/m | −516.58% (below 0%: shrinking) | 70.97% | (3.86%) | Compare |
| VMD Viemed Healthcare, Inc. | $343.2M | 22.0× | 23.4× | +12.18% (above 0%: growing) | +33.33% (above 0%: growing) | −67.55% (below 0%: shrinking) | 57.26% | 0.00% | Compare |
| CV CapsoVision, Inc. | $329.9M | — (loss-making) | — (loss-making) | +9.89% (above 0%: growing) | n/m | −84.44% (below 0%: shrinking) | 51.36% | (208.07%) | |
| CLPT ClearPoint Neuro, Inc. | $278.6M | — (loss-making) | — (loss-making) | +36.27% (above 0%: growing) | n/m | −58.10% (below 0%: shrinking) | 58.46% | (52.44%) | Compare |
| TMCI Treace Medical Concepts, Inc. | $271.9M | — (loss-making) | — (loss-making) | −4.24% (below 0%: shrinking) | n/m | +11.74% (above 0%: growing) | 78.47% | (32.96%) | Compare |
| Median of peers | $369.4M | — | — | +35.85% | — | −34.85% | 76.55% | (25.45%) |
Pay and ownership Proxy statement filed 28 April 2026
Ownership
Directors and executive officers, together
2.30%
Ching-Hang Shen
12.80%
Eliyahou Harari
10.20%
KIOXIA Corporation
6.90%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement